Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Brainsway, boosting the price target to $18.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Ram Selvaraju has given his Buy rating due to a combination of factors, including Brainsway’s recent FDA label expansion for its Deep TMS system. This expansion allows the system to be used as an adjunct therapy for adolescents with major depressive disorder, broadening its market potential. Additionally, the company has shown a strong revenue performance with a 29% increase in 3Q25, surpassing expectations.
Furthermore, Brainsway’s strategic approach, including multi-year lease agreements and minority equity investments, provides a solid foundation for future growth. The company’s increased performance obligations and a growing installed base of Deep TMS systems contribute to a positive outlook. Despite a modest bottom-line miss, the overall financial health, including a significant cash reserve, supports the Buy rating.
Selvaraju covers the Healthcare sector, focusing on stocks such as Bioxcel Therapeutics, Emergent Biosolutions, and Genmab. According to TipRanks, Selvaraju has an average return of 23.3% and a 51.40% success rate on recommended stocks.
In another report released yesterday, Ladenburg Thalmann & Co. also reiterated a Buy rating on the stock with a $19.00 price target.